- Home
- CELC vs MTLS Comparison
CELC vs MTLS Comparison
Compare CELC & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- MTLS
- Stock Information
- Founded
- CELC 2011
- MTLS 1990
- Country
- CELC United States
- MTLS Belgium
- Employees
- CELC N/A
- MTLS N/A
- Industry
- CELC Medical Specialities
- MTLS Computer Software: Prepackaged Software
- Sector
- CELC Health Care
- MTLS Technology
- Exchange
- CELC Nasdaq
- MTLS Nasdaq
- Market Cap
- CELC 489.7M
- MTLS 467.2M
- IPO Year
- CELC 2017
- MTLS 2014
- Fundamental
- Price
- CELC $10.93
- MTLS $7.64
- Analyst Decision
- CELC Strong Buy
- MTLS Buy
- Analyst Count
- CELC 6
- MTLS 1
- Target Price
- CELC $29.17
- MTLS $9.50
- AVG Volume (30 Days)
- CELC 356.6K
- MTLS 184.2K
- Earning Date
- CELC 11-14-2024
- MTLS 02-19-2025
- Dividend Yield
- CELC N/A
- MTLS N/A
- EPS Growth
- CELC N/A
- MTLS 323.01
- EPS
- CELC N/A
- MTLS 0.19
- Revenue
- CELC N/A
- MTLS $297,100,156.00
- Revenue This Year
- CELC N/A
- MTLS $8.48
- Revenue Next Year
- CELC N/A
- MTLS $9.65
- P/E Ratio
- CELC N/A
- MTLS $40.29
- Revenue Growth
- CELC N/A
- MTLS 5.07
- 52 Week Low
- CELC $10.35
- MTLS $4.70
- 52 Week High
- CELC $22.19
- MTLS $8.50
- Technical
- Relative Strength Index (RSI)
- CELC 35.65
- MTLS 53.87
- Support Level
- CELC $10.35
- MTLS $6.98
- Resistance Level
- CELC $13.80
- MTLS $8.10
- Average True Range (ATR)
- CELC 0.83
- MTLS 0.40
- MACD
- CELC -0.19
- MTLS 0.02
- Stochastic Oscillator
- CELC 16.20
- MTLS 65.98
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, Poland, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.